Table 1 Demographic, clinical and tumour-related characteristics of patients included in the study (n = 62)
From: Glyceraldehyde-3-phosphate dehydrogenase is overexpressed in colorectal cancer onset
Age (years)a | 69.5 ± 11.4 | |
|---|---|---|
Gender – n° (%) | Male | 45 (72.6) |
Female | 17 (27.4) | |
Family history of colorectal cancer – n° (%) | 10 (16.1) | |
Fulfillment of revised Bethesda guidelines – n° (%) | 14 (22.6) | |
Tumour location – n° (%) | Proximal to splenic flexure | 19 (30.6) |
Distal to splenic flexure | 43 (69.4) | |
TNM tumour stage – n° (%) | I | 9 (14.5) |
II | 21 (33.9) | |
III | 16 (25.8) | |
IV | 16 (25.8) | |
Tumour size (mm)a | 43 ± 20 | |
Differentiation degree – n° (%) | Well | 6 (9.7) |
Moderate | 51 (82.2) | |
Poor | 5 (8.1) | |
Mucinous carcinoma type – n° (%) | 10 (16.1) | |
Mismatch repair deficiency – n° (%)b | 4 (6.5) | |
Synchronous colorectal cancer – n° (%) | 5 (8.1) | |
Synchronous colorectal adenoma – n° (%) | 23 (37.1) | |
Surgical treatment – n° (%) | Right colectomy | 16 (25.8) |
Left colectomy | 6 (9.7) | |
Sigmoidectomy | 22 (35.5) | |
Anterior resection | 9 (14.5) | |
Total colectomy | 6 (9.7) | |
Abdominoperineal resection (Miles) | 3 (4.8) | |
Chemotherapy – n° (%)c | 35 (56.5) | |
Length of follow-up (months)d | 49 (40–53) |